NZ600887A - Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts - Google Patents

Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts

Info

Publication number
NZ600887A
NZ600887A NZ600887A NZ60088709A NZ600887A NZ 600887 A NZ600887 A NZ 600887A NZ 600887 A NZ600887 A NZ 600887A NZ 60088709 A NZ60088709 A NZ 60088709A NZ 600887 A NZ600887 A NZ 600887A
Authority
NZ
New Zealand
Prior art keywords
cancer
leukaemia
small cell
benzimidazol
methylpiperazin
Prior art date
Application number
NZ600887A
Other languages
English (en)
Inventor
Danielle Giron
Walter Hammerschmidt
Philippe Piechon
Johanne Polasek
Andreas Schreiner
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ600887(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ600887A publication Critical patent/NZ600887A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ600887A 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts NZ600887A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19
NZ587829A NZ587829A (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Publications (1)

Publication Number Publication Date
NZ600887A true NZ600887A (en) 2013-10-25

Family

ID=40622140

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ600887A NZ600887A (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts
NZ587829A NZ587829A (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ587829A NZ587829A (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Country Status (24)

Country Link
US (1) US8563556B2 (https=)
EP (1) EP2257544B1 (https=)
JP (1) JP2011515370A (https=)
KR (1) KR20100137517A (https=)
CN (1) CN101970425B (https=)
AR (1) AR070924A1 (https=)
AU (1) AU2009227003B2 (https=)
BR (1) BRPI0909762A2 (https=)
CA (1) CA2718076A1 (https=)
CL (1) CL2009000651A1 (https=)
CO (1) CO6321253A2 (https=)
EC (1) ECSP10010555A (https=)
IL (1) IL208020A0 (https=)
MA (1) MA32230B1 (https=)
MX (1) MX2010010152A (https=)
MY (1) MY150554A (https=)
NZ (2) NZ600887A (https=)
PE (1) PE20091628A1 (https=)
PH (2) PH12012502568A1 (https=)
RU (1) RU2497820C2 (https=)
SG (1) SG188919A1 (https=)
TW (1) TWI426072B (https=)
WO (1) WO2009115562A2 (https=)
ZA (1) ZA201006263B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
ES2707625T3 (es) 2010-04-16 2019-04-04 Novartis Ag Compuesto orgánico para su utilización en el tratamiento del cáncer de hígado
NZ602807A (en) 2010-04-16 2014-02-28 Novartis Ag 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
WO2012125812A1 (en) 2011-03-17 2012-09-20 Novartis Ag Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
BR112013029246A2 (pt) 2011-05-19 2017-02-14 Novartis Ag 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
JP2014526506A (ja) 2011-09-15 2014-10-06 ノバルティス アーゲー 中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
US20150202203A1 (en) 2012-07-11 2015-07-23 Novartis Ag Method of Treating Gastrointestinal Stromal Tumors
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ304344B6 (cs) * 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
AU2003290699B2 (en) 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
KR101387985B1 (ko) * 2005-01-27 2014-04-25 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 전이 종양의 치료
MX2007014782A (es) * 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
RU2433826C2 (ru) * 2005-11-29 2011-11-20 Новартис Аг Композиции хинолинонов
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme

Also Published As

Publication number Publication date
NZ587829A (en) 2012-08-31
KR20100137517A (ko) 2010-12-30
WO2009115562A2 (en) 2009-09-24
EP2257544A2 (en) 2010-12-08
WO2009115562A3 (en) 2009-11-26
AU2009227003A1 (en) 2009-09-24
AR070924A1 (es) 2010-05-12
PH12012502569A1 (en) 2015-09-21
MA32230B1 (fr) 2011-04-01
MX2010010152A (es) 2010-10-25
RU2497820C2 (ru) 2013-11-10
CN101970425A (zh) 2011-02-09
TW201000463A (en) 2010-01-01
AU2009227003B2 (en) 2013-03-14
CO6321253A2 (es) 2011-09-20
ECSP10010555A (es) 2010-11-30
HK1147492A1 (en) 2011-08-12
IL208020A0 (en) 2010-12-30
CN101970425B (zh) 2014-04-16
CA2718076A1 (en) 2009-09-24
CL2009000651A1 (es) 2010-07-19
JP2011515370A (ja) 2011-05-19
EP2257544B1 (en) 2014-12-03
ZA201006263B (en) 2011-05-25
TWI426072B (zh) 2014-02-11
US8563556B2 (en) 2013-10-22
US20110021536A1 (en) 2011-01-27
RU2010142396A (ru) 2012-04-27
PH12012502568A1 (en) 2014-10-27
PE20091628A1 (es) 2009-11-19
MY150554A (en) 2014-01-30
BRPI0909762A2 (pt) 2018-04-03
SG188919A1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
NZ600887A (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts
JP2011515370A5 (https=)
HRP20230400T1 (hr) Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
TR201819653T4 (tr) Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik.
JP2017528475A5 (https=)
RU2015104537A (ru) Способы лечения стромальных опухолей желудочно-кишечного тракта
NZ593114A (en) Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors
JP2017526662A5 (https=)
MY177994A (en) Therapeutically active compounds and their methods of use
JP2017512791A5 (https=)
JP2015512398A5 (https=)
JP2014502638A5 (https=)
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
HRP20131081T1 (hr) Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera
JP2018531226A5 (https=)
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
HRP20160472T4 (hr) Postupak liječenja proliferativnih bolesti i ostalih patoloških stanja posredovanih djelovanjem kinaze od bcr-abl, c-kit, ddr1, ddr2 ili pdgf-r
HRP20150778T1 (hr) Derivati hidroksamske kiseline
JP2016525076A5 (https=)
TR201010618A2 (tr) İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
JP2017519019A5 (https=)
NZ599217A (en) Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
JP2012526766A5 (https=)
JP2012509265A5 (https=)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 MAR 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2017 BY CPA GLOBAL

Effective date: 20160205

LAPS Patent lapsed